Commercial-stage precision diagnostics company MDxHealth ( NASDAQ: MDXH ) reported preliminary Q2 and H1 2024 results, expects revenues of ~$22.2M and $42M, respectively, representing Y/Y growth of 32% and 34%. This represents a sequential growth from Q1 of 12%.
The company is raising its FY 2024 revenue guidance from $83M-$85M to $85M-$87M, representing 23% Y/Y revenue growth at the midpoint of guidance. The company’s cash balance as of June 30, 2024, was $21.3 million.
The stock price gained 6.8% to $2.50 on Monday.
More on MDxHealth SA MDxHealth SA (MDXH) Q1 2024 Earnings Call Transcript Financial information for MDxHealth SA.